ERBB2 and breast neoplasm: Our findings identify miR-770-5p as a tumor suppressor in breast tumors, acting as a regulatory switch that targets key players such as EGFR, HER2, IGF1R, as well as downstream effectors including AKT, ERK, and mTOR.